Orforglipron (Foundayo): Dosing and Drug Profile
Also known as: Foundayo
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Eli Lilly |
| Mechanism | GLP-1 receptor agonist (non-peptide small molecule) |
| Administration | Once-daily oral pill — no food or water restrictions |
| Peak weight loss | ~12.4% at 72 weeks (ATTAIN-1) |
| Status | FDA-approved April 2026 — first non-peptide oral GLP-1 agonist |
Where is the oral titration schedule?
The daily-pill schedule is on the Foundayo explainer (card below) — this profile does not repeat the dose table.
Deep dive
Foundayo (Orforglipron): Lilly's Oral GLP-1 Pill Explained →Eli Lilly's FDA-approved oral GLP-1 pill — 12.4% weight loss, no injections, no fasting. Starting at $149/month.
Orforglipron (Foundayo) compared
Every head-to-head we've published involving Orforglipron (Foundayo).
Orforglipron vs Tirzepatide (Zepbound): Oral Pill vs Weekly Injection
Orforglipron offers 12.4% weight loss as a daily pill. Tirzepatide delivers 22.5% as a weekly injection. Both are from Eli Lilly.
Updated February 2026
Orforglipron vs Zepbound (Tirzepatide): Daily Pill vs Weekly Injection
Orforglipron offers 12.4% weight loss as a daily pill starting at $149/month. Zepbound delivers 22.5% as a weekly injection at $299-$449/month. Both from Eli Lilly.
Updated March 2026
Retatrutide vs Orforglipron: Injectable Triple Agonist vs Oral GLP-1
Retatrutide produces 28.7% weight loss via injection. Orforglipron offers 12.4% weight loss as a daily pill. Both are from Eli Lilly.
Updated February 2026
Orforglipron vs Rybelsus (Oral Semaglutide): Two Oral GLP-1 Pills Compared
Orforglipron has no food restrictions and beat Rybelsus on weight loss in ACHIEVE-3. Rybelsus requires fasting but is available now.
Updated March 2026
Related articles
Safety, mechanism, and context pieces that reference Orforglipron (Foundayo).
Retatrutide Pill vs Injection: Is There an Oral Formulation?
Retatrutide is injection-only. Here's why there's no pill, how the injection works, and how oral GLP-1 alternatives compare.
Updated February 2026
NBC TODAY on Foundayo (Oral GLP-1 Pill): Fact Check
TODAY called it Zepbound — it's actually Foundayo. Weight loss data and pricing are accurate. Full fact check inside.
Updated April 2026
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.